RSS
Home
Biotech arthritis drugs get cancer warning
Print
Email
RSS
Subscribe
National Institutes of Health
Lymphomas, leukemia and other cancers have developed among some patients taking bioengineered anti-inflammatory drugs. In light of these cases, the U.S. Food and Drug Administration is asking the makers of the medications to add new warnings to their products' prescribing information.
The products--known as tumor necrosis factor alpha blockers--affected by the agency's decision are Remicade (infliximab), Enbrel (etancercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab). Each will also carry a new warning about the possible onset of new psoriasis among users.
The most severe problems have occurred among patients younger than 18 years of age, showing up an average of 30 months after the children began using the drugs.
The medications treat juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ankylosing spondylitis
Related Articles:
Add a Comment
